GlassScriptPhysician profile
Michael Cheshire
NPI 1215218771
$1,163.67
in general payments reported to CMS, 2019-2025
13 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $127 · 2021: $11.11 · 2022: $40.06 · 2023: $180 · 2024: $82.41 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $414.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $604.48 | 2019-2025 | Ozempic, Wegovy |
| Janssen Scientific Affairs, LLC | $130.63 | 2023 | Xarelto |
| Pfizer INC. | $108.15 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $72.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $64.63 | 2024 | |
| Abbvie INC. | $30.31 | 2022-2023 | Vraylar |
| Solventum Corporation | $27.76 | 2025 | V.A.C.Ulta |
| Phadia US INC. | $26.47 | 2019-2020 | |
| Allergan, INC. | $26.19 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $26.05 | 2019 | |
| Abbott Laboratories | $21.14 | 2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $14.91 | 2019 | |
| Amgen INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cheshire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.